Trial Profile
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs OBT 357 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Acronyms ARMY
- Sponsors Menarini
- 05 Jul 2021 Status changed from active, no longer recruiting to discontinued.
- 11 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.
- 11 May 2021 Status changed from recruiting to active, no longer recruiting.